These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 15143997

  • 21. 5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer.
    Meyer L, Hildebrandt B, Riess H.
    Oncology; 2003; 64(4):473-4. PubMed ID: 12759548
    [No Abstract] [Full Text] [Related]

  • 22. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [Abstract] [Full Text] [Related]

  • 23. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [Abstract] [Full Text] [Related]

  • 24. Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapy.
    Chu E.
    Clin Colorectal Cancer; 2005 Jul; 5(2):80-1. PubMed ID: 16098246
    [No Abstract] [Full Text] [Related]

  • 25. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
    Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC, Tang LN, Zhang W.
    Chin Med J (Engl); 2006 Nov 05; 119(21):1829-33. PubMed ID: 17097039
    [No Abstract] [Full Text] [Related]

  • 26. The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer.
    Chu E.
    Clin Colorectal Cancer; 2005 Jan 05; 4(5):292. PubMed ID: 15663830
    [No Abstract] [Full Text] [Related]

  • 27. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
    Berg D.
    Oncol Nurs Forum; 2003 Jan 05; 30(6):957-66. PubMed ID: 14603353
    [Abstract] [Full Text] [Related]

  • 28. [Colorectal carcinoma].
    Schulthess G, Kolyvanos Naumann U, Käser L, Vetter W.
    Praxis (Bern 1994); 2005 Nov 02; 94(44):1705-11; quiz 1712. PubMed ID: 16309014
    [No Abstract] [Full Text] [Related]

  • 29. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD.
    Clin Colorectal Cancer; 2001 Aug 02; 1(2):85-6. PubMed ID: 12445365
    [No Abstract] [Full Text] [Related]

  • 30. Oxaliplatin in colorectal cancer: current studies.
    Goldberg R.
    Oncology (Williston Park); 2000 Dec 02; 14(12 Suppl 11):42-7. PubMed ID: 11204663
    [Abstract] [Full Text] [Related]

  • 31. Current status of adjuvant therapy for colorectal cancer.
    O'Connell MJ.
    Oncology (Williston Park); 2004 May 02; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
    [Abstract] [Full Text] [Related]

  • 32. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B, Cantagalli E, Amalfitano ME.
    Tumori; 2005 May 02; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract] [Full Text] [Related]

  • 33. [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
    Shimoyama S, Kondo K, Kataoka M.
    Nihon Rinsho; 2003 Sep 02; 61 Suppl 7():356-9. PubMed ID: 14574912
    [No Abstract] [Full Text] [Related]

  • 34. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C, George T, Yothers G.
    J Natl Cancer Inst; 2011 Jan 05; 103(1):4-5. PubMed ID: 21123834
    [No Abstract] [Full Text] [Related]

  • 35. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
    Hoff PM, Pazdur R.
    Oncology (Williston Park); 1999 Jul 05; 13(7 Suppl 3):48-50. PubMed ID: 10442361
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of oxaliplatin in the treatment of colorectal cancer.
    Rothenberg ML.
    Oncology (Williston Park); 2000 Dec 05; 14(12 Suppl 11):9-14. PubMed ID: 11204666
    [Abstract] [Full Text] [Related]

  • 37. Developments in combination chemotherapy for colorectal cancer.
    Goetz MP, Grothey A.
    Expert Rev Anticancer Ther; 2004 Aug 05; 4(4):627-37. PubMed ID: 15270666
    [Abstract] [Full Text] [Related]

  • 38. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C, Abbruzzese JL.
    Clin Adv Hematol Oncol; 2004 Sep 05; 2(9):592-8. PubMed ID: 16163242
    [Abstract] [Full Text] [Related]

  • 39. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR.
    Clin Colorectal Cancer; 2011 Sep 05; 10(3):203-6. PubMed ID: 21855044
    [No Abstract] [Full Text] [Related]

  • 40. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.
    Bull Cancer; 2016 Jun 05; 103(6):541-51. PubMed ID: 27155924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.